MetLife Investment Advisors LLC Takes $31.03 Million Position in Bristol-Myers Squibb (BMY)

MetLife Investment Advisors LLC purchased a new position in Bristol-Myers Squibb (NYSE:BMY) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 506,408 shares of the biopharmaceutical company’s stock, valued at approximately $31,033,000.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in Bristol-Myers Squibb by 0.3% in the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after purchasing an additional 333,685 shares during the last quarter. BlackRock Inc. lifted its position in Bristol-Myers Squibb by 5.0% in the 4th quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock valued at $6,391,093,000 after purchasing an additional 4,945,515 shares during the last quarter. Dodge & Cox lifted its position in Bristol-Myers Squibb by 1.6% in the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after purchasing an additional 459,271 shares during the last quarter. Jennison Associates LLC lifted its position in Bristol-Myers Squibb by 16.2% in the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after purchasing an additional 3,735,453 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Bristol-Myers Squibb by 3.9% in the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after purchasing an additional 910,496 shares during the last quarter. Institutional investors own 71.53% of the company’s stock.

Several analysts recently weighed in on the stock. Vetr downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price objective on the stock. in a research report on Thursday, February 8th. BMO Capital Markets cut their price objective on shares of Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 6th. Leerink Swann lifted their price objective on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research report on Tuesday, February 6th. Citigroup set a $78.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, February 16th. Finally, Jefferies Group set a $70.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Friday, March 23rd. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $66.68.



Bristol-Myers Squibb stock opened at $60.18 on Thursday. The stock has a market cap of $98,738.62, a price-to-earnings ratio of 19.99, a P/E/G ratio of 1.57 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. Bristol-Myers Squibb has a 52 week low of $51.56 and a 52 week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion for the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. Bristol-Myers Squibb’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter last year, the company earned $0.63 EPS. research analysts forecast that Bristol-Myers Squibb will post 3.22 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be paid a $0.40 dividend. The ex-dividend date is Thursday, April 5th. This represents a $1.60 annualized dividend and a dividend yield of 2.66%. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.

ILLEGAL ACTIVITY WARNING: “MetLife Investment Advisors LLC Takes $31.03 Million Position in Bristol-Myers Squibb (BMY)” was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://dakotafinancialnews.com/2018/04/12/metlife-investment-advisors-llc-takes-31-03-million-position-in-bristol-myers-squibb-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply